Which has stronger valuation and earnings, PASG or ELTX?

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A Elicio Therapeutics N/A N/A -$39.57M -$2.40 N/A

Is PASG or ELTX more profitable?

Passage Bio's return on equity of -150.88% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Elicio Therapeutics N/A -2,748.16% -151.12%

Does the media favor PASG or ELTX?

In the previous week, Passage Bio and Passage Bio both had 2 articles in the media. Passage Bio's average media sentiment score of 0.00 equaled Elicio Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elicio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation & earnings, IMMP or PASG?

Prima BioMed has higher revenue and earnings than Passage Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.46 -$39.78M N/A N/A Passage Bio N/A N/A -$45.52M -$11.84 N/A

Is IMMP or PASG more profitable?

Prima BioMed's return on equity of 0.00% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Passage Bio N/A -150.88% -59.78%

Which has higher valuation & earnings, PASG or CNTX?

Context Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A Context Therapeutics N/A N/A -$36.12M -$0.48 N/A

Is PASG or CNTX more profitable?

Context Therapeutics' return on equity of -82.06% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Context Therapeutics N/A -82.06% -72.74%

Does the media favor PASG or CNTX?

In the previous week, Context Therapeutics had 13 more articles in the media than Passage Bio. MarketBeat recorded 15 mentions for Context Therapeutics and 2 mentions for Passage Bio. Context Therapeutics' average media sentiment score of 0.08 beat Passage Bio's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Context Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is INO or PASG more profitable?

Passage Bio's return on equity of -150.88% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -489.79% -95.40% Passage Bio N/A -150.88% -59.78%

Does the media refer more to INO or PASG?

In the previous week, Inovio Pharmaceuticals had 2 more articles in the media than Passage Bio. MarketBeat recorded 4 mentions for Inovio Pharmaceuticals and 2 mentions for Passage Bio. Inovio Pharmaceuticals' average media sentiment score of 0.54 beat Passage Bio's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, PASG or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A

Is PASG or INKT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% MiNK Therapeutics N/A N/A -118.57%

Does the media favor PASG or INKT?

In the previous week, MiNK Therapeutics had 3 more articles in the media than Passage Bio. MarketBeat recorded 5 mentions for MiNK Therapeutics and 2 mentions for Passage Bio. MiNK Therapeutics' average media sentiment score of 0.30 beat Passage Bio's score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiNK Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Passage Bio (PASG) Competitors

$4.32 -0.08 (-1.82%)

As of 04:00 PM Eastern

Compare

PASG vs. ELTX, IMMP, CNTX, INO, and INKT

Should you buy Passage Bio stock or one of its competitors? MarketBeat compares Passage Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Passage Bio include Elicio Therapeutics (ELTX), Prima BioMed (IMMP), Context Therapeutics (CNTX), Inovio Pharmaceuticals (INO), and MiNK Therapeutics (INKT). These companies are all part of the "biotechnology" industry.

How does Passage Bio compare to Elicio Therapeutics?

Passage Bio (NASDAQ:PASG) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Passage Bio presently has a consensus price target of $13.25, indicating a potential upside of 206.71%. Elicio Therapeutics has a consensus price target of $19.75, indicating a potential upside of 537.10%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Elicio Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A

Passage Bio has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

Passage Bio's return on equity of -150.88% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

In the previous week, Passage Bio and Passage Bio both had 2 articles in the media. Passage Bio's average media sentiment score of 0.00 equaled Elicio Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elicio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 28.7% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Elicio Therapeutics beats Passage Bio on 6 of the 11 factors compared between the two stocks.

How does Passage Bio compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Prima BioMed has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

Prima BioMed has higher revenue and earnings than Passage Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.46	-$39.78M	N/A	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

Prima BioMed's return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Passage Bio	N/A	-150.88%	-59.78%

Prima BioMed presently has a consensus price target of $5.50, suggesting a potential upside of 1,331.92%. Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 206.71%. Given Prima BioMed's higher possible upside, research analysts plainly believe Prima BioMed is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

In the previous week, Passage Bio had 2 more articles in the media than Prima BioMed. MarketBeat recorded 2 mentions for Passage Bio and 0 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Company	Overall Sentiment
Prima BioMed	Neutral
Passage Bio	Neutral

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 4.9% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Prima BioMed beats Passage Bio on 6 of the 11 factors compared between the two stocks.

How does Passage Bio compare to Context Therapeutics?

Passage Bio (NASDAQ:PASG) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Passage Bio has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

Passage Bio currently has a consensus target price of $13.25, suggesting a potential upside of 206.71%. Context Therapeutics has a consensus target price of $6.17, suggesting a potential upside of 1,263.40%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Context Therapeutics' return on equity of -82.06% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Context Therapeutics	N/A	-82.06%	-72.74%

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Context Therapeutics had 13 more articles in the media than Passage Bio. MarketBeat recorded 15 mentions for Context Therapeutics and 2 mentions for Passage Bio. Context Therapeutics' average media sentiment score of 0.08 beat Passage Bio's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Summary

Context Therapeutics beats Passage Bio on 9 of the 13 factors compared between the two stocks.

How does Passage Bio compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 4.9% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Inovio Pharmaceuticals currently has a consensus target price of $3.25, suggesting a potential upside of 341.34%. Passage Bio has a consensus target price of $13.25, suggesting a potential upside of 206.71%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Inovio Pharmaceuticals is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Passage Bio has lower revenue, but higher earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,009.73	-$84.95M	-$1.45	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

Passage Bio's return on equity of -150.88% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
Passage Bio	N/A	-150.88%	-59.78%

In the previous week, Inovio Pharmaceuticals had 2 more articles in the media than Passage Bio. MarketBeat recorded 4 mentions for Inovio Pharmaceuticals and 2 mentions for Passage Bio. Inovio Pharmaceuticals' average media sentiment score of 0.54 beat Passage Bio's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inovio Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Summary

Inovio Pharmaceuticals beats Passage Bio on 8 of the 14 factors compared between the two stocks.

How does Passage Bio compare to MiNK Therapeutics?

Passage Bio (NASDAQ:PASG) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Passage Bio has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

MiNK Therapeutics' return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
MiNK Therapeutics	N/A	N/A	-118.57%

In the previous week, MiNK Therapeutics had 3 more articles in the media than Passage Bio. MarketBeat recorded 5 mentions for MiNK Therapeutics and 2 mentions for Passage Bio. MiNK Therapeutics' average media sentiment score of 0.30 beat Passage Bio's score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiNK Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

Passage Bio currently has a consensus price target of $13.25, indicating a potential upside of 206.71%. MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 221.10%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 4.9% of Passage Bio shares are held by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

MiNK Therapeutics beats Passage Bio on 9 of the 14 factors compared between the two stocks.

Get Passage Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PASG vs. The Competition

Export

Metric	Passage Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.87M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.36	9.13	269.75	24.73
Price / Sales	N/A	1,274.20	652.34	108.63
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.73	17.66	11.27	6.42
Net Income	-$45.52M	-$13.25M	$3.45B	$347.12M
7 Day Performance	-3.79%	5.36%	3.56%	2.48%
1 Month Performance	-5.47%	-1.74%	-0.58%	-1.04%
1 Year Performance	-31.10%	61.36%	77.52%	23.22%

Passage Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PASG Passage Bio	3.0503 of 5 stars	$4.32 -1.8%	$13.25 +206.7%	-29.8%	$13.87M	N/A	N/A	130	Earnings Report
ELTX Elicio Therapeutics	2.1269 of 5 stars	$3.11 +8.6%	$19.75 +536.1%	-65.3%	$58.89M	N/A	N/A	N/A	News Coverage
IMMP Prima BioMed	2.2247 of 5 stars	$0.39 +3.0%	$5.50 +1,303.1%	-78.4%	$57.77M	$6.69M	N/A	2,021	Positive News
CNTX Context Therapeutics	2.9416 of 5 stars	$0.63 +3.5%	$6.17 +886.7%	-32.8%	$57.52M	N/A	N/A	7	News Coverage Earnings Report Analyst Revision
INO Inovio Pharmaceuticals	2.3503 of 5 stars	$0.67 -3.3%	$3.25 +382.2%	-52.6%	$55.45M	$60K	N/A	320	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PASG) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Passage Bio (PASG) Competitors

PASG vs. ELTX, IMMP, CNTX, INO, and INKT

How does Passage Bio compare to Elicio Therapeutics?

Summary

How does Passage Bio compare to Prima BioMed?

Summary

How does Passage Bio compare to Context Therapeutics?

Summary

How does Passage Bio compare to Inovio Pharmaceuticals?

Summary

How does Passage Bio compare to MiNK Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Passage Bio (PASG) Competitors

PASG vs. ELTX, IMMP, CNTX, INO, and INKT

How does Passage Bio compare to Elicio Therapeutics?

Do analysts rate PASG or ELTX?

Which has stronger valuation and earnings, PASG or ELTX?

Which has more volatility and risk, PASG or ELTX?

Is PASG or ELTX more profitable?

Does the media favor PASG or ELTX?

Do institutionals & insiders have more ownership in PASG or ELTX?

Summary

How does Passage Bio compare to Prima BioMed?

Which has more volatility and risk, IMMP or PASG?

Which has higher valuation & earnings, IMMP or PASG?

Is IMMP or PASG more profitable?

Do analysts recommend IMMP or PASG?

Does the media refer more to IMMP or PASG?

Do institutionals and insiders believe in IMMP or PASG?

Summary

How does Passage Bio compare to Context Therapeutics?

Which has more volatility & risk, PASG or CNTX?

Do analysts prefer PASG or CNTX?

Is PASG or CNTX more profitable?

Do institutionals & insiders hold more shares of PASG or CNTX?

Does the media favor PASG or CNTX?

Which has higher valuation & earnings, PASG or CNTX?

Summary

How does Passage Bio compare to Inovio Pharmaceuticals?

Do institutionals and insiders have more ownership in INO or PASG?

Do analysts prefer INO or PASG?

Which has better earnings and valuation, INO or PASG?

Is INO or PASG more profitable?

Does the media refer more to INO or PASG?

Which has more volatility and risk, INO or PASG?

Summary

How does Passage Bio compare to MiNK Therapeutics?

Which has more volatility & risk, PASG or INKT?

Is PASG or INKT more profitable?

Does the media favor PASG or INKT?

Which has better earnings and valuation, PASG or INKT?

Do analysts prefer PASG or INKT?

Do institutionals & insiders believe in PASG or INKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools